KNSA Relative Valuation
KNSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KNSA is overvalued; if below, it's undervalued.
Historical Valuation
Kiniksa Pharmaceuticals International PLC (KNSA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -289.71. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：40.99
Fair
21.86
PE
1Y
3Y
5Y
Trailing
Forward
19.36
EV/EBITDA
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBITDA of 19.36. The 5-year average EV/EBITDA is -26.79. The thresholds are as follows: Strongly Undervalued below -326.80, Undervalued between -326.80 and -176.80, Fairly Valued between 123.21 and -176.80, Overvalued between 123.21 and 273.22, and Strongly Overvalued above 273.22. The current Forward EV/EBITDA of 19.36 falls within the Historic Trend Line -Fairly Valued range.
21.61
EV/EBIT
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBIT of 21.61. The 5-year average EV/EBIT is 1.17. The thresholds are as follows: Strongly Undervalued below -76.25, Undervalued between -76.25 and -37.54, Fairly Valued between 39.89 and -37.54, Overvalued between 39.89 and 78.60, and Strongly Overvalued above 78.60. The current Forward EV/EBIT of 21.61 falls within the Historic Trend Line -Fairly Valued range.
3.66
PS
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current PS of 3.66. The 5-year average PS is 11.40. The thresholds are as follows: Strongly Undervalued below -58.22, Undervalued between -58.22 and -23.41, Fairly Valued between 46.20 and -23.41, Overvalued between 46.20 and 81.01, and Strongly Overvalued above 81.01. The current Forward PS of 3.66 falls within the Historic Trend Line -Fairly Valued range.
-66.16
P/OCF
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/OCF of -66.16. The 5-year average P/OCF is 195.01. The thresholds are as follows: Strongly Undervalued below -1875.92, Undervalued between -1875.92 and -840.46, Fairly Valued between 1230.48 and -840.46, Overvalued between 1230.48 and 2265.95, and Strongly Overvalued above 2265.95. The current Forward P/OCF of -66.16 falls within the Historic Trend Line -Fairly Valued range.
45.69
P/FCF
Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/FCF of 45.69. The 5-year average P/FCF is -32.89. The thresholds are as follows: Strongly Undervalued below -359.50, Undervalued between -359.50 and -196.20, Fairly Valued between 130.41 and -196.20, Overvalued between 130.41 and 293.72, and Strongly Overvalued above 293.72. The current Forward P/FCF of 45.69 falls within the Historic Trend Line -Fairly Valued range.
Kiniksa Pharmaceuticals International PLC (KNSA) has a current Price-to-Book (P/B) ratio of 5.77. Compared to its 3-year average P/B ratio of 3.44 , the current P/B ratio is approximately 67.88% higher. Relative to its 5-year average P/B ratio of 3.66, the current P/B ratio is about 57.79% higher. Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.82%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.49% , the current FCF yield is about -100.00% lower.
5.77
P/B
Median3y
3.44
Median5y
3.66
3.31
FCF Yield
Median3y
1.82
Median5y
-4.49
Competitors Valuation Multiple
The average P/S ratio for KNSA's competitors is , providing a benchmark for relative valuation. Kiniksa Pharmaceuticals International PLC Corp (KNSA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 61.17%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of KNSA increased by 107.23% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 26.12 to 87.80.
The secondary factor is the Revenue Growth, contributed 61.17%to the performance.
Overall, the performance of KNSA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Kiniksa Pharmaceuticals International PLC (KNSA) currently overvalued or undervalued?
What is Kiniksa Pharmaceuticals International PLC (KNSA) fair value?
How does KNSA's valuation metrics compare to the industry average?
What is the current P/B ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Dec 05 2025?
What is the current FCF Yield for Kiniksa Pharmaceuticals International PLC (KNSA) as of Dec 05 2025?
What is the current Forward P/E ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Dec 05 2025?